Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
This randomized phase II trial studies how well obinutuzumab with or without umbralisib,
lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa
follicular lymphoma that has come back or does not respond to treatment. Immunotherapy with
monoclonal antibodies, such as obinutuzumab, may help the body''s immune system attack the
cancer, and may interfere with the ability of the tumor cells to grow and spread. Umbralisib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Biological therapies, such as lenalidomide, use substances made from living organisms that
may stimulate or suppress the immune system in different ways and stop cancer cells from
growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride,
vincristine sulfate, prednisone, and bendamustine, work in different ways to stop the growth
of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. It is not yet known whether giving obinutuzumab with or without
umbralisib, lenalidomide, or combination chemotherapy will work better in treating patients
with grade I-IIIa follicular lymphoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.